about
Ranolazine for stable angina pectorisRanolazine: A Contemporary ReviewClassification of drugs based on properties of sodium channel inhibition: a comparative automated patch-clamp studyMembrane transporters in drug developmentClinical Implications of P-Glycoprotein Modulation in Drug-Drug Interactions.Management standards for stable coronary artery disease in India.Complexity of ranolazine and phenytoin use in an infant with long QT syndrome type 3.Update on ranolazine in the management of angina.Emerging clinical role of ranolazine in the management of angina.A rare debilitating neurological adverse effect of ranolazine due to drug interaction with clarithromycinAnti-anginal and anti-ischemic effects of late sodium current inhibitionFlip-flop pharmacokinetics--delivering a reversal of disposition: challenges and opportunities during drug developmentA new system for profiling drug-induced calcium signal perturbation in human embryonic stem cell-derived cardiomyocytes.Pharmacological and non pharmacological strategies in the management of coronary artery disease and chronic kidney diseaseRanolazine attenuated heightened plasma norepinephrine and B-Type natriuretic peptide-45 in improving cardiac function in rats with chronic ischemic heart failure.A rare neurological complication of ranolazine.Safety and Efficacy of Ranolazine for the Treatment of Chronic Angina Pectoris.Ranolazine: an anti-anginal drug with further therapeutic potential.Should ranolazine be used for all patients with ischemic heart disease or only for symptomatic patients with stable angina or for those with refractory angina pectoris? A critical appraisal.Ranolazine: a review of its use as add-on therapy in patients with chronic stable angina pectoris.Ranolazine: clinical applications and therapeutic basis.Stable angina pectoris.Ranolazine treatment for myocardial infarction? Effects on the development of necrosis, left ventricular function and arrhythmias in experimental models.Coronary artery disease in the military patient.Evaluation and Quantitative Prediction of Renal Transporter-Mediated Drug-Drug Interactions.Ranolazine for stable angina pectoris.Antiarrhythmic properties of ranolazine--from bench to bedside.Ranolazine can markedly increase tacrolimus blood levels.Drug Interaction between Sirolimus and Ranolazine in a Kidney Transplant Patient.Ranolazine decreases mechanosensitivity of the voltage-gated sodium ion channel Na(v)1.5: a novel mechanism of drug action.Neurologic adverse effects of ranolazine in an elderly patient with renal impairment.Ranolazine-tacrolimus interaction.Influence of quercetin on the pharmacokinetics of ranolazine in rats and in vitro models.Clinical experience with ranolazine in a veteran population with chronic stable angina.Drug-drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug.Ranolozine-induced suppression of ventricular tachycardia in a patient with nonischemic cardiomyopathy: a case report.Expert consensus document: A 'diamond' approach to personalized treatment of angina.Antiarrhythmic Effects of Combining Dofetilide and Ranolazine in a Model of Acutely Induced Atrial Fibrillation in Horses.Effects of ranolazine in a model of doxorubicin-induced left ventricle diastolic dysfunction.Pharmacokinetic drug-drug interaction study of ranolazine and metformin in subjects with type 2 diabetes mellitus.
P2860
Q24187560-691AE079-B8B8-4881-A60F-9613ADD11773Q26765421-56B4B593-4D9C-4753-AD19-2655C3C94D02Q28476574-4F78B056-801E-4770-BB43-8A2FB8F681E0Q29616802-0F631A0A-BC3D-44DE-BF23-BC741C3080F9Q30234940-8D743BB6-C2F3-40D8-9987-F626A429BD17Q30239853-3B039087-754C-4EE6-8018-F4E95C99827BQ33644474-A70E001D-2212-48C9-A196-B344689CCE9CQ33831222-DECACE17-0A92-43CD-8105-B07B872BA7B5Q34235939-DFCD8271-8848-4EB0-96D0-C890DF423DB1Q34247689-006F63F8-E15F-4596-AB4B-C830A41794DCQ35147202-4C9DD64B-9578-46C8-9CD2-CABE74EAF58FQ35153417-D80CD05C-918D-46D0-A1EE-FCD609C17F14Q35181854-6F8F0F9F-33D2-4D40-884F-890AD2E03971Q36021782-EA054457-458D-4DB7-B4AB-FCCE83D888C7Q36841418-828CEA3D-C90B-4577-B4E1-1691EB77FD54Q37018984-9A804A01-FC9F-486E-BC16-C3D0734D3183Q37599625-612965E9-2042-4DC4-A698-27357A1013D3Q37707393-1F9DEFB9-B619-4443-8F79-9359FE993CF4Q38057398-2E071886-CCED-4DEF-ABF6-BCCBCA05E274Q38074900-CA1F34EE-476E-49E9-87A8-89F4960B1523Q38075519-650CCE5A-77F8-4C94-B0AE-6AE8131DF23BQ38212580-124A7E3D-8C2F-4932-8499-12B394D74754Q38238926-F51BFA45-179F-428E-A048-808674DCDC12Q38561463-3DE9E51C-DF75-4636-A2C4-23FA2285087FQ38844658-65C1CA2B-B5F3-49F1-B87C-A324CD5301B8Q38971758-CB350290-A7DD-4A33-833D-BF48364B38E1Q39564664-4E073779-AB1C-4EF9-A886-F5DD1A39473BQ40336819-DD9382FA-27F8-4F85-8C15-6C2958C63D06Q41906583-E9135794-CC34-422C-A139-460FACA9EF6AQ42230425-B2B2BD69-5690-4952-B416-18DA0DB78C2CQ42279222-ECDA2803-A038-470E-A231-346590FDF4BAQ42874658-34D7C645-747B-4E0A-A811-422742C14A77Q44451449-CE67E306-3B09-4863-8A6C-BE729F0D8812Q45330316-A7D6E057-C9F9-4E4F-8B7E-E2585C9414A3Q46261836-7E6B18EF-391B-4E7C-B444-6659D5C36FE7Q46571842-41E3C193-6A91-4155-9DE8-25E4BADF7FBEQ48022963-FB13E4C4-4F38-4B2F-9417-3ABE544FF727Q49183821-A5D79477-0DB4-4E0D-B925-A19327573032Q51093490-4D1A3652-B75E-4080-A639-8C853EF880FAQ51738040-5E5E85AE-2AFA-4455-A913-E37BA56867E3
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Clinical pharmacokinetics of ranolazine.
@ast
Clinical pharmacokinetics of ranolazine.
@en
type
label
Clinical pharmacokinetics of ranolazine.
@ast
Clinical pharmacokinetics of ranolazine.
@en
prefLabel
Clinical pharmacokinetics of ranolazine.
@ast
Clinical pharmacokinetics of ranolazine.
@en
P1476
Clinical pharmacokinetics of ranolazine.
@en
P2093
Markus Jerling
P2860
P304
P356
10.2165/00003088-200645050-00003
P577
2006-01-01T00:00:00Z
P6179
1031726754